Skip to headlines
clockwire Search
LIVE
Fate of Trump's new FDA commissioner nominee will fall on Senate Democrats Citi downgrades New York Times, flags weakening user engagement, monetization EXCLUSIVE: Glenavon 'going to do everything we can to keep' talisman amid Irish League transfer interest Save big on Proton VPN – great speed and privacy for just $2.49 per month Apple’s 20th anniversary iPhone could ditch bezels almost entirely, and I’m trying not to get too excited Samsung kickstarts One UI 9.5 Beta Program, and there’s plenty to get excited about MacPaw brings its security app to iPhone, and it can spot scam texts before you fall for them Protests in France: What to expect on Saturday November 21st Bangladesh under pressure as they fight for a draw against Proteas Why is Arm stock gaining today? Yemen Law Criminalizes Houthi Activities, Opens Door to Domestic and International Prosecution UiPath falls as Cleveland Research sees downside risks for ARR Why is Amazon stock climbing today? The worst offending NHS trusts for snooping on patient files revealed Ithaca Energy outlines $560M-$580M 2026 dividend guidance while targeting 140,000-150,000 boe/d in the medium term
‹ Back to your news

MARKETS

Tempus AI to receive $200M as AstraZeneca extends oncology deal

Covered by 1 source First reported

How each outlet tells it

Seeking Alpha (US) · private

Tempus AI to receive $200M as AstraZeneca extends oncology deal

Read at Seeking Alpha